Drug Trial Radar · NCT01589978
PROMUS Element Plus US Post-Approval Study
Last checked: Nov 20, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,681
Actual
Start
May 2012
Primary completion
Aug 2014
Study completion Jun 2018
Sponsor
- Lead sponsor
- Boston Scientific CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice. Patients will have symptomatic heart disease or documented silent ischemia. This is a prospective, open-label consecutively-enrolling study. Clinical follow-up is through 5 years. Approximately 2,689 patients are to be enrolled in up to 65 centers in the United States.
Conditions
- Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent SystemDevice
PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
AspirinDrug
Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
P2Y12 antagonistDrug
Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI. * Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily) * Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling) * Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided. * Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiac Death or Myocardial Infarction Rate in PLATINUM-like PatientsTime frame: 12 months
Locations
52 sites in 1 country. Site status is shown where the registry gives one.
Huntsville Hospital - The Heart Center, PC
Huntsville, Alabama
Springhill Medical Center
Mobile, Alabama
NEA Baptist Memorial Hospital
Jonesboro, Arkansas
St. Bernard's Medical Center
Jonesboro, Arkansas
Loma Linda University Medical Center
Loma Linda, California
Mercy General Hospital
Sacramento, California
Christiana Hospital
Newark, Delaware
Brandon Regional Hospital
Brandon, Florida
North Florida Regional Medical Center
Gainesville, Florida
Memorial Regional Hospital
Hollywood, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Orlando Regional Medical Center
Orlando, Florida
Bay Medical Center
Panama City, Florida
Martin Memorial Health Systems - Martin Memorial Medical Center
Stuart, Florida
Piedmont Hospital
Atlanta, Georgia
Coliseum Medical Center
Macon, Georgia
Redmond Regional Medical Center
Rome, Georgia
Blessing Hospital
Quincy, Illinois
IU Health North Medical Center
Carmel, Indiana
Franciscan St. Francis Hospital
Indianapolis, Indiana
Community Heart and Vascular Hospital
Indianapolis, Indiana
St. Joseph Hospital
Lexington, Kentucky
Cardiovascular Research, LLC
Shreveport, Louisiana
Eastern Maine Medical Center
Bangor, Maine
Cape Cod Hospital
Hyannis, Massachusetts
Lakeland Hospitals at St. Joseph
Saint Joseph, Michigan
Mercy Hospital
Coon Rapids, Minnesota
North Memorial Medical Center
Minneapolis, Minnesota
United Hospital - St. Paul Heart Clinic
Saint Paul, Minnesota
Forest County General Hospital
Hattiesburg, Mississippi
St. John's Regional Health Center (Springfield)
Springfield, Missouri
Cox Medical Centers
Springfield, Missouri
Hackensack University Medical Center
Hackensack, New Jersey
New York University Medical Center
New York, New York
St. Elizabeth Medical Center
Utica, New York
Novant Health Presbyterian Medical Center
Charlotte, North Carolina
St. Francis Hospital
Tulsa, Oklahoma
Doylestown Hospital
Doylestown, Pennsylvania
Presbyterian University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
University Medical Center-Greenville Memorial Hospital
Greenville, South Carolina
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.